Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Glycaemic control in labour with diabetes (GILD)

Diabetes in pregnancy affects at least 5% of pregnant women. For most women this is gestational diabetes (GDM) (87.5%), but 12.5% women have pre-existing diabetes.

There is evidence that ‘tight’ glycaemic control in pregnancy reduces the risk of adverse outcomes for the mother and the baby. Traditionally ‘tight’ glucose control (target 4-7 mmol/L) is recommended in labour. Treatment with intravenous insulin may be needed during labour to maintain ‘tight’ control, however, this increases the risk of maternal hypoglycaemia in labour, which carries a risk to the mother.

Hourly intrapartum testing is also intrusive for women and time consuming for health care practitioners. Conversely, accepting more permissive glucose levels in the mother may be detrimental to the baby. Maternal hyperglycaemia results in increased fetal insulin production because of excess placental transfer of glucose and can lead to neonatal hypoglycaemia.

This study will assess whether it is feasible to run a trial to assess the clinical and cost-effectiveness of permissive versus intensive intrapartum glycaemic control in women with pregnancies complicated by diabetes.

Oxford project lead:

Collaborators:

Nia Jones, University of Nottingham

Dates:

February 2021 – January 2023

Funder:

National Institute for Health Research (Health Technology Assessment Programme)

Our team